385 related articles for article (PubMed ID: 27527508)
1. Cost-effectiveness of percutaneous coronary intervention with cobalt-chromium everolimus eluting stents versus bare metal stents: Results from a patient level meta-analysis of randomized trials.
Ferko N; Ferrante G; Hasegawa JT; Schikorr T; Soleas IM; Hernandez JB; Sabaté M; Kaiser C; Brugaletta S; de la Torre Hernandez JM; Galatius S; Cequier A; Eberli F; de Belder A; Serruys PW; Valgimigli M
Catheter Cardiovasc Interv; 2017 May; 89(6):994-1002. PubMed ID: 27527508
[TBL] [Abstract][Full Text] [Related]
2. Economic Outcomes of Bioresorbable Vascular Scaffolds Versus Everolimus-Eluting Stents in Patients Undergoing Percutaneous Coronary Intervention: 1-Year Results From the ABSORB III Trial.
Baron SJ; Lei Y; Chinnakondepalli K; Vilain K; Magnuson EA; Kereiakes DJ; Ellis SG; Stone GW; Cohen DJ;
JACC Cardiovasc Interv; 2017 Apr; 10(8):774-782. PubMed ID: 28427593
[TBL] [Abstract][Full Text] [Related]
3. Everolimus-Eluting Stents in Patients With Bare-Metal and Drug-Eluting In-Stent Restenosis: Results From a Patient-Level Pooled Analysis of the RIBS IV and V Trials.
Alfonso F; Pérez-Vizcayno MJ; García Del Blanco B; García-Touchard A; López-Mínguez JR; Masotti M; Zueco J; Melgares R; Mainar V; Moreno R; Domínguez A; Sanchís J; Bethencourt A; Moreu J; Cequier A; Martí V; Otaegui I; Bastante T; Gonzalo N; Jiménez-Quevedo P; Cárdenas A; Fernández C;
Circ Cardiovasc Interv; 2016 Jul; 9(7):. PubMed ID: 27412868
[TBL] [Abstract][Full Text] [Related]
4. Health Economic Evaluation of an Ultrathin, Bioresorbable-Polymer Sirolimus-Eluting Coronary Stent Compared to a Thin, Durable-Polymer Everolimus-Eluting Stent.
Mattke S; Hanson M; Dallmann AC; Bentele M
Cardiovasc Revasc Med; 2019 Sep; 20(9):752-757. PubMed ID: 30638888
[TBL] [Abstract][Full Text] [Related]
5. Four-year comparative effectiveness of bare-metal and everolimus-eluting stents in New York.
Qian F; Zhong Y; Hannan EL
Catheter Cardiovasc Interv; 2018 Feb; 91(3):417-424. PubMed ID: 28557275
[TBL] [Abstract][Full Text] [Related]
6. Impact of stent diameter and length on in-stent restenosis after DES vs BMS implantation in patients needing large coronary stents-A clinical and health-economic evaluation.
Zbinden R; von Felten S; Wein B; Tueller D; Kurz DJ; Reho I; Galatius S; Alber H; Conen D; Pfisterer M; Kaiser C; Eberli FR
Cardiovasc Ther; 2017 Feb; 35(1):19-25. PubMed ID: 27662632
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy outcomes of second-generation everolimus-eluting stents in octogenarians compared to non-octogenarians.
Kitabata H; Kubo T; Mori K; Yamamoto Y; Kashiwagi M; Arita Y; Tanimoto T; Akasaka T
Cardiovasc Revasc Med; 2018 Jan; 19(1 Pt A):12-16. PubMed ID: 28600019
[TBL] [Abstract][Full Text] [Related]
8. Randomized comparison of cost-saving and effectiveness of oral rapamycin plus bare-metal stents with drug-eluting stents: three-year outcome from the randomized oral rapamycin in Argentina (ORAR) III trial.
Rodriguez AE; Rodriguez-Granillo AM; Antoniucci D; Mieres J; Fernandez-Pereira C; Rodriguez-Granillo GA; Santaera O; Rubilar B; Palacios IF; Serruys PW;
Catheter Cardiovasc Interv; 2012 Sep; 80(3):385-94. PubMed ID: 22109997
[TBL] [Abstract][Full Text] [Related]
9. Comparing Stent Thrombosis associated with Zotarolimus Eluting Stents versus Everolimus Eluting Stents at 1 year follow up: a systematic review and meta-analysis of 6 randomized controlled trials.
Bundhun PK; Yanamala CM; Huang WQ
BMC Cardiovasc Disord; 2017 Mar; 17(1):84. PubMed ID: 28302055
[TBL] [Abstract][Full Text] [Related]
10. Comparison of newer-generation drug-eluting with bare-metal stents in patients with acute ST-segment elevation myocardial infarction: a pooled analysis of the EXAMINATION (clinical Evaluation of the Xience-V stent in Acute Myocardial INfArcTION) and COMFORTABLE-AMI (Comparison of Biolimus Eluted From an Erodible Stent Coating With Bare Metal Stents in Acute ST-Elevation Myocardial Infarction) trials.
Sabaté M; Räber L; Heg D; Brugaletta S; Kelbaek H; Cequier A; Ostojic M; Iñiguez A; Tüller D; Serra A; Baumbach A; von Birgelen C; Hernandez-Antolin R; Roffi M; Mainar V; Valgimigli M; Serruys PW; Jüni P; Windecker S
JACC Cardiovasc Interv; 2014 Jan; 7(1):55-63. PubMed ID: 24332419
[TBL] [Abstract][Full Text] [Related]
11. Small-vessel PCI outcomes in men, women, and minorities following platinum chromium everolimus-eluting stents: Insights from the pooled PLATINUM Diversity and PROMUS Element Plus Post-Approval studies.
Guedeney P; Claessen BE; Mehran R; Kandzari DE; Aquino M; Davis S; Tamis L; Wang JC; Othman I; Gigliotti OS; Haghighat A; Singh S; Lopez M; Giugliano G; Horwitz PA; Sorrentino S; Underwood P; Allocco D; Meredith IT; Batchelor W
Catheter Cardiovasc Interv; 2019 Jul; 94(1):82-90. PubMed ID: 30666784
[TBL] [Abstract][Full Text] [Related]
12. Long-term clinical and angiographic outcomes of percutanenous coronary intervention with everolimus-eluting stents for the treatment of cardiac allograft vasculopathy.
Cheng R; Vanichsarn C; Patel JK; Currier J; Chang DH; Kittleson MM; Makkar R; Kobashigawa JA; Azarbal B
Catheter Cardiovasc Interv; 2017 Jul; 90(1):48-55. PubMed ID: 27862865
[TBL] [Abstract][Full Text] [Related]
13. 5-Year Outcome Following Randomized Treatment of All-Comers With Zotarolimus-Eluting Resolute Integrity and Everolimus-Eluting PROMUS Element Coronary Stents: Final Report of the DUTCH PEERS (TWENTE II) Trial.
Zocca P; Kok MM; Tandjung K; Danse PW; Jessurun GAJ; Hautvast RWM; van Houwelingen KG; Stoel MG; Schramm AR; Tjon Joe Gin RM; de Man FHAF; Hartmann M; Louwerenburg JHW; Linssen GCM; Löwik MM; Doggen CJM; von Birgelen C
JACC Cardiovasc Interv; 2018 Mar; 11(5):462-469. PubMed ID: 29519378
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness analysis of biodegradable polymer versus durable polymer drug-eluting stents incorporating real-world evidence.
Teng M; Zhao YJ; Khoo AL; Ananthakrishna R; Yeo TC; Lim BP; Chan MY; Loh JP
Cardiovasc Ther; 2018 Oct; 36(5):e12442. PubMed ID: 29873191
[TBL] [Abstract][Full Text] [Related]
15. The EXAMINATION trial (Everolimus-Eluting Stents Versus Bare-Metal Stents in ST-Segment Elevation Myocardial Infarction): 2-year results from a multicenter randomized controlled trial.
Sabaté M; Brugaletta S; Cequier A; Iñiguez A; Serra A; Hernádez-Antolín R; Mainar V; Valgimigli M; Tespili M; den Heijer P; Bethencourt A; Vázquez N; Backx B; Serruys PW
JACC Cardiovasc Interv; 2014 Jan; 7(1):64-71. PubMed ID: 24332423
[TBL] [Abstract][Full Text] [Related]
16. Comparison between catheter-based delivery of paclitaxel after bare-metal stenting and drug-eluting stents in coronary artery disease patients at high risk for in-stent restenosis.
El-Mokadem M; El-Ramly M; Hassan A; Boshra H; AbdelWahab A
Cardiovasc Revasc Med; 2017 Dec; 18(8):596-600. PubMed ID: 28625402
[TBL] [Abstract][Full Text] [Related]
17. Clinical outcomes with bioabsorbable polymer- versus durable polymer-based drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis.
Palmerini T; Biondi-Zoccai G; Della Riva D; Mariani A; Sabaté M; Smits PC; Kaiser C; D'Ascenzo F; Frati G; Mancone M; Genereux P; Stone GW
J Am Coll Cardiol; 2014 Feb; 63(4):299-307. PubMed ID: 24211507
[TBL] [Abstract][Full Text] [Related]
18. Biodegradable Polymer Biolimus-Eluting Stents Versus Durable Polymer Everolimus-Eluting Stents in Patients With Coronary Artery Disease: Final 5-Year Report From the COMPARE II Trial (Abluminal Biodegradable Polymer Biolimus-Eluting Stent Versus Durable Polymer Everolimus-Eluting Stent).
Vlachojannis GJ; Smits PC; Hofma SH; Togni M; Vázquez N; Valdés M; Voudris V; Slagboom T; Goy JJ; den Heijer P; van der Ent M
JACC Cardiovasc Interv; 2017 Jun; 10(12):1215-1221. PubMed ID: 28579236
[TBL] [Abstract][Full Text] [Related]
19. Drug-Eluting Balloons Versus Everolimus-Eluting Stents for In-Stent Restenosis: A Meta-Analysis of Randomized Trials.
Elgendy IY; Mahmoud AN; Elgendy AY; Mojadidi MK; Elbadawi A; Eshtehardi P; Pérez-Vizcayno MJ; Wayangankar SA; Jneid H; David Anderson R; Alfonso F
Cardiovasc Revasc Med; 2019 Jul; 20(7):612-618. PubMed ID: 30126824
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of everolimus-eluting stents in the treatment of drug-eluting stent versus bare-metal stent restenosis.
Almalla M; Pross V; Marx N; Hoffmann R
Coron Artery Dis; 2012 Nov; 23(7):492-6. PubMed ID: 22990414
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]